CD8A and neoplasm: In addition, different DC subsets also induce different tumor-specific immune responses, as vaccination with murine cDC1s induced a prominent CD8+ T-cell driven anti-tumor immune response that was beneficial in tumors with abundant Tregs whereas cDC2s induced a Th17-mediated anti-tumor immune response that was advantageous in tumors with TAMs (33, 34).